Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

10    Johnson & Johnson    $12.1B     down 6.2%
Global revenue: $65.0B (2nd); up 5.5%

R&D spend: $7.5B (5th), up 10.3%; 11.5% of rev.

Top brands: Remicade ($3.5B), Procrit ($1.2B), Concerta ($856M), Levaquin ($778), Prezista ($630M)

Planned launches: Canagliflozin (diab.), TMC-435 (HCV), bapineuzumab (Alz.)

Promotional spend: $438M (13th); 3.6% of rev.

Patent expirations: Remicade (2014), Prezista (2016), Zytiga (2016)

J&J's past year can be summed up in one word: recalls. The healthcare products giant had a lot of them, fueling discussions of a company that has lost its luster. This came in addition to lawsuits alleging fraudulent marketing of its antipsychotic Risperdal. The impact of these missteps shows: the government shutdown of a McNeil plant hurt inventory levels, and OTC sales fell 3% in the US last year. But a recent poll showed consumers are still attached to J&J. CEO William Weldon, who was in place during much of the product recalls, was replaced by Alex Gorsky.

Back to first page

Page 10 of 21
Share this article:

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.